Salmeterol/fluticasone propionate combination in the treatment of COPD.
Chronic obstructive pulmonary disease (COPD) is characterized by poorly reversible airway obstruction and progressive airway inflammation. The long-acting beta2-agonist salmeterol and the corticosteroid fluticasone propionate can be administered in a combination inhaler. Four double-blind, placebo-controlled, randomized clinical trials have demonstrated that salmeterol/fluticasone propionate improves pulmonary function and health status, and also decreases exacerbation rates in COPD patients. The TORCH (Towards a Revolution in COPD Health) study confirmed that the effects of combined therapy with salmeterol/fluticasone propionate are greater than the monocomponents. The TORCH data are also indicative of a beneficial effect of salmeterol/fluticasone propionate on mortality, although there is much debate about this issue. This review critically appraises the pharmacology of salmeterol/fluticasone propionate, the evidence for efficacy in COPD and its potential use in combination with other drugs.
Singh
S Dave
SD
University of Manchester, North West Lung Research Centre, South Manchester, University Hospital Trust, Manchester, M33 3TR, UK. dsingh@meu.org.uk